Biopharmaceutical News and Research

RSS

Enterin and Parkinson's Virtual Biotech collaborate to study the effects of ENT-01 on PD-associated dementia

Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative and metabolic diseases announces a collaboration with the Parkinson's Virtual Biotech, the drug development and discovery arm of Parkinson's UK.

13 Oct 2022

Sartorius releases the 6th edition of its popular live-cell analysis handbook

Sartorius, a leader in new technologies for real-time, live-cell imaging and analysis, has released the 6th edition of its popular Live-Cell Analysis Handbook.

From Sartorius 10 Oct 2022

New lab technique could spark a 'paradigm shift' in testing protein-based drugs

New Jersey Institute of Technology researchers have unveiled a new lab technique they say represents a "paradigm shift" in how pharmaceutical laboratories test and produce new protein-based drugs, such as therapeutic monoclonal antibodies being developed to treat a variety of diseases, from cancers to infectious diseases.

27 Sep 2022

New board members bring significant leadership experience in the biotech sector

Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease, is pleased to announce the appointment of three new members to its Board of Directors: Dr. Nancy Krieger, Dr. Don Haut, and Dr. Devyn Smith.

From Aspect Biosystems 22 Sep 2022

ValitaCell joins Beckman Coulter Life Sciences

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, announces it has acquired ValitaCell Ltd., a biotechnology company that creates pioneering analytical products and technologies for the biopharmaceutical industry.

From Beckman Coulter Life Sciences 16 Sep 2022

PhoreMost enters multi-project drug target discovery collaboration with Roche

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes

From PhoreMost 6 Sep 2022

Alternative approaches to functional and phenotypic assays using multi-parameter flow cytometry

Synexa is an industry-leading biomarker and large molecule bio analytic research service provider. In this interview, NewsMedical speaks with Natalie Strickland, a principal scientist at Synexa, about alternative approaches to flow cytometry.

From Synexa Life Sciences 5 Sep 2022

Quality Control in Food and Beverage Production

In this interview, News-Medical Life Sciences talks to Angela Visgandis, Product Specialist at Thermo Fisher Scientific about how quality control in the food and beverage industry has changed over the years.

From Thermo Fisher Scientific – Laboratory Products Division – Food & Beverage Quality Control 11 Aug 2022

New compound proves to be potent against more than 300 drug-resistant bacteria

Urinary tract infections are common, yet are increasingly tough to treat because the bacteria that cause them are becoming resistant to many antibiotics.

10 Aug 2022

Turning to Organ-on-a-Chip Studies for the Future of Drug Discovery

In this interview, we speak to Tom Kostrzewski, VP of Science and Technology at CN Bio, about their organ-on-a-chip product and the future of drug discovery.

From CN Bio 3 Aug 2022

ACROBiosystems was titled 2022 CiteAb Awards protein supplier winner, gaining global scientific approval

Recently, ACROBiosystems won Cite Awards, being titled "the Winner of Protein Supplier to Watch in 2022".

From ACROBiosystems 1 Aug 2022

IVI successfully completes the '2022 Introductory Course for Biologics Development and Manufacturing'

The International Vaccine Institute (IVI) successfully completed the '2022 Introductory Course for Biologics Development and Manufacturing' on July 29 to train 106 participants from 24 low- and middle-income countries (LMICs) and 32 from the Republic of Korea.

29 Jul 2022

Cytokine-based cancer immunotherapy: current progress and future prospects

In this interview, News-Medical talks to Dr. Shuang Zhou about cytokine-base cancer immunotherapy, the current state of the field, and future prospects.

From Sino Biological Inc. 18 Jul 2022

Novel technique could offer an improved route to drug discovery and development

A new technique that can analyze how drug molecules bind to proteins in tissue samples could offer an improved route to drug discovery and development.

14 Jul 2022

Orbit Discovery awarded Innovate UK grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discovery

Orbit Discovery Ltd., (“Orbit”) a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has been awarded a Smart grant by Innovate UK, the UK’s innovation agency.

From Orbit Discovery 14 Jun 2022

Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA)

From Curia 9 Jun 2022

Misinformation clouds America’s most popular emergency contraception

A brand of specialty mozzarella cheeses. A collection of natural-gas storage terminals. And America’s top-selling emergency contraception.

7 Jun 2022

Curia Adopts the Berkeley Lights Platform to Expand its Antibody Discovery Capabilities

Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and Curia, formerly AMRI, a leading contract research, development and manufacturing organization (CDMO), today announced Curia’s adoption of The Beacon® Optofluidic system and workflows from Berkeley Lights to accelerate and expand its antibody-based drug discovery capabilities.

From Bruker Cellular Analysis 6 Jun 2022

MD Anderson and National Resilience launch the Cell Therapy Manufacturing Center

The University of Texas MD Anderson Cancer Center and National Resilience, Inc., today announced the launch of a joint venture, the Cell Therapy Manufacturing Center, to accelerate the development and manufacturing of innovative cell therapies for patients with cancer.

2 Jun 2022

Case Western Reserve signs license agreement to bring groundbreaking AI for helping cancer patients

When Case Western Reserve University research showed that artificial intelligence (AI) could identify which lung cancer patients would benefit from chemotherapy, a national magazine called the finding one of the "10 Most Incredible Medical Breakthroughs of 2018."

25 May 2022